RESULTS:
The intervals of the GADD between the current and earliest spontaneous preterm birth in weeks by treatment group are depicted in the histogram in Figure 1A . A GADD of 3 weeks or more (dark line) would label 73% of women in the placebo group and 78% in the 17-alpha hydroxyprogesterone caproate group as responsive to treatment and thus could not define responsiveness to 17-alpha hydroxyprogesterone caproate. Using the median interval of the GADD of 5 weeks in the placebo group as a threshold to define 17-alpha hydroxyprogesterone caproate responsiveness resulted in a similar overlap of success between the placebo and 17-alpha hydroxyprogesterone caproate groups, 56% vs 60% (P ¼ .421). When the 3 week GADD proposed by Manuck et al 1e3 was limited only to those delivering spontaneously at <37 weeks (n ¼ 159), the success rate for the 17-alpha hydroxyprogesterone caproate group would label 48% in the 17-alpha hydroxyprogesterone caproate group and 54% in the placebo group as being responsive to 17-alpha hydroxyprogesterone caproate. The distribution of these intervals of the GADD is depicted by the dark line in Figure 1B . We repeated these analyses of the GADD reported in previous text using intervals between the current pregnancy and the last pregnancy as opposed to the earliest prior spontaneous preterm birth; the findings demonstrated a similar overlap in success between the 17-alpha hydroxyprogesterone caproate and placebo groups without an ability to distinguish success between the 2 groups.
CONCLUSION:
We have demonstrated that 17-alpha hydroxyprogesterone caproate responsiveness cannot be defined by a prolongation of 3 or more weeks from the earliest prior spontaneous preterm birth to the currently treated pregnancy. We evaluated other intervals of the GADD and could not demonstrate any threshold of the intervals of the GADD between placebo-or 17-alpha hydroxyprogesterone caproateetreated women that might be used to define an effect of 17-alpha hydroxyprogesterone caproate. Based on the findings in this analysis, responsiveness to 17-alpha hydroxyprogesterone caproate based on the intervals of the GADD should be abandoned and conclusions reached in prior publications that utilized this criterion should be reassessed.
-
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Female pelvic medicine and reconstructive surgery fellows' exposure to transgender health care
OBJECTIVE:
The American Congress of Obstetricians and Gynecologists stated that obstetrician-gynecologists "should be prepared to assist or refer transgender individuals with routine treatment and screening, as well as hormonal and surgical therapies." 1,2 Surgical therapies include gender confirmation surgery (GCS) to phenotypically align a person's sexual characteristics with their gender identity. A survey of obstetrician-gynecologists demonstrated that 80% did not receive training in residency on the care of transgender individuals. 3 Our objective was to assess exposure to patients who are transgender among female pelvic medicine and reconstructive surgery (FPMRS) fellows.
STUDY DESIGN:
We administered an anonymous survey to FPMRS fellows during a fellows' meeting at the 2015 American Urogynecologic Society Annual Meeting. In the absence of a validated tool, we developed the survey based on our experience with fellowship training and in caring for transgender patients. One of the authors (Y.G.-C.), who has expertise in GCS, reviewed the survey for content validity. Survey items included demographics as well as educational and clinical exposure to transgender health care. Fellows were asked about their ability to perform female-to-male (FTM) GCS, defined as hysterectomy with bilateral salpingooophorectomy, and comfort with counseling and caring for patients after GCS. We performed statistical analyses using software (SAS 9.4; SAS Institute Inc, Cary, NC). The institutional review board approved this study.
RESULTS:
In all, 76 of 97 fellows (78%) who received the survey responded. In 2015, there were 155 FPMRS fellows in training. Most fellows reported no experience with inpatient (84%) or outpatient (74%) care of transgender patients. At institutions where FTM GCS was performed, 88% of fellows believed that they would be able to provide a FTM hysterectomy with salpingo-oophorectomy after training, compared to 33% at institutions where FTM GCS was not performed (P < .001). Most fellows (70%) reported that they had no didactics on transgender health care during fellowship. Fellows who had at least 1 hour of didactic training were significantly more likely to report that they would be comfortable managing surgical complications from FTM GCS (74%) compared to those who had not (47%; P ¼ .047) (Table) .
CONCLUSION:
We distributed our survey to a convenience sample of the 155 FPMRS fellows in 2015. Although we did not Data are presented as n (%); survey response options were dichotomous (yes or no).
GCS, gender confirmation surgery.
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